UBS Group
KPTI icon

UBS Group’s Karyopharm Therapeutics KPTI Stock Holding History

UBS Group’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,820
Closed -$423K – 9257
2020
Q4 		$423K Buy
+1,820
New +$422K ﹤0.01% 4728

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

UBS Group's KPTI Position: Q1 2026 in Review

UBS Group increased its Karyopharm Therapeutics (KPTI) stake by 119% in Q1 2026, buying an estimated $805K and bringing the position to 194,017 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #5498.

UBS Group first reported a position in KPTI in Q4 2014 and has held it in 46 quarters since. The position peaked at $6.95M in Q4 2014. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • UBS Group held 194,017 shares of Karyopharm Therapeutics worth $1.08M as of Q1 2026.
  • UBS Group bought 105,562 Karyopharm Therapeutics shares in Q1 2026, an estimated $805K.
  • Karyopharm Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5498 holding.
  • UBS Group first reported a position in Karyopharm Therapeutics in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Karyopharm Therapeutics position peaked at $6.95M in Q4 2014.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.